MCID: INN002
MIFTS: 51

Inner Ear Disease

Categories: Ear diseases, Rare diseases

Aliases & Classifications for Inner Ear Disease

MalaCards integrated aliases for Inner Ear Disease:

Name: Inner Ear Disease 12 15
Labyrinthine Dysfunction 12 15 73
Abnormality of the Inner Ear 6
Labyrinthine Disorder 73
Diseases of Inner Ear 73
Labyrinthine Disease 12
Labyrinth Diseases 44

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases


Summaries for Inner Ear Disease

MalaCards based summary : Inner Ear Disease, also known as labyrinthine dysfunction, is related to autoimmune inner ear disease and superior semicircular canal dehiscence, and has symptoms including vertigo and earache. An important gene associated with Inner Ear Disease is FGF3 (Fibroblast Growth Factor 3), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Gap junction trafficking. The drugs Glucosamine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Inner Ear Disease

Diseases in the Inner Ear Disease family:

Autoimmune Inner Ear Disease

Diseases related to Inner Ear Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 autoimmune inner ear disease 34.3 MPO TIMP1 TNF
2 superior semicircular canal dehiscence 31.7 COCH RTEL1
3 auditory system disease 29.8 ATP6V1B1 CDH23 COCH GJB2 GJB3 GJB6
4 bilateral hyperactive labyrinth 11.4
5 unilateral hyperactive labyrinth 11.4
6 bilateral hypoactive labyrinth 11.4
7 unilateral hypoactive labyrinth 11.2
8 tietz albinism-deafness syndrome 11.1
9 usher syndrome 11.1
10 meniere disease 11.0
11 usher syndrome, type i 11.0
12 usher syndrome, type iiia 11.0
13 deafness, congenital, with inner ear agenesis, microtia, and microdontia 11.0
14 mondini dysplasia 11.0
15 otodental dysplasia 10.3 FADD FGF3
16 deafness, autosomal recessive 3 10.3 GJB2 MYO7A
17 microscopic polyangiitis 10.3 MPO TNF
18 deafness, autosomal dominant 24 10.3 GJB2 GJB6
19 hypotrichosis-deafness syndrome 10.3 GJB2 GJB3
20 deafness, autosomal recessive 93 10.3 GJB2 GJB3
21 appendicitis 10.2 MPO TIMP1 TNF
22 knuckle pads, leukonychia, and sensorineural deafness 10.2 GJB2 GJB6
23 ear malformation 10.2 FGF3 GJB2 SLC26A4
24 post-transplant lymphoproliferative disease 10.2 B2M FADD TNF
25 pleural tuberculosis 10.2 B2M TIMP1 TNF
26 anca-associated vasculitis 10.2 MPO TNF
27 deafness, x-linked 2 10.2 GJB2 GJB6
28 deafness, autosomal recessive 28 10.2 GJB2 GJB3
29 peritonitis 10.2 B2M MPO TNF
30 kid syndrome 10.2 GJB2 GJB3 GJB6
31 pseudoainhum 10.2 GJB2 GJB3 GJB6
32 deafness, autosomal recessive 1a 10.2 GJB2 GJB3 GJB6
33 knuckle pads 10.2 GJB2 GJB3 GJB6
34 membranous nephropathy 10.2 B2M MPO TNF
35 dfnb1 10.2 GJB2 GJB6 MYO7A
36 drug-induced hearing loss 10.2 GJB2 GJB3 SLC26A4
37 erythrokeratodermia variabilis et progressiva 1 10.2 GJB2 GJB3 GJB6
38 clouston syndrome 10.2 GJB2 GJB3 GJB6
39 auditory neuropathy spectrum disorder 10.2 MT-RNR1 MYO7A
40 deafness, autosomal dominant 36 10.2 GJB2 MT-RNR1 SLC26A4
41 vohwinkel syndrome 10.2 GJB2 GJB6
42 autosomal recessive nonsyndromic deafness 10.2 CDH23 GJB2 SLC26A4
43 peripheral vertigo 10.2 COCH RTEL1 SLC26A4
44 medullary sponge kidney 10.2 ATP6V0A4 ATP6V1B1
45 renal tubular acidosis, distal 10.2 ATP6V0A4 ATP6V1B1
46 deafness, autosomal dominant 22 10.2 COCH MYH9 MYO7A
47 retinitis pigmentosa-deafness syndrome 10.1 CDH23 MYO7A
48 deafness, autosomal recessive 26 10.1 CDH23 GJB2 SLC26A4
49 renal tubular acidosis, distal, autosomal recessive 10.1 ATP6V0A4 ATP6V1B1
50 usher syndrome, type ig 10.1 CDH23 MYO7A

Comorbidity relations with Inner Ear Disease via Phenotypic Disease Network (PDN):


Hypertension, Essential Ischemic Heart Disease
Labyrinthitis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Inner Ear Disease:



Diseases related to Inner Ear Disease

Symptoms & Phenotypes for Inner Ear Disease

UMLS symptoms related to Inner Ear Disease:


vertigo, earache

MGI Mouse Phenotypes related to Inner Ear Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ATP6V0A4 ATP6V1B1 B2M CDH23 COL4A5 FADD
2 cardiovascular system MP:0005385 10.17 B2M COL4A5 FADD GJB2 GJB3 GJB6
3 growth/size/body region MP:0005378 10.14 ATP6V0A4 B2M CDH23 FADD FGF3 GJB2
4 hearing/vestibular/ear MP:0005377 10.11 ATP6V0A4 ATP6V1B1 CDH23 COCH FGF3 GJB2
5 immune system MP:0005387 10.07 B2M COL4A5 FADD FGF3 GJB2 GJB3
6 mortality/aging MP:0010768 9.93 ATP6V0A4 B2M COL4A5 FADD FGF3 GJB2
7 nervous system MP:0003631 9.77 ATP6V1B1 B2M CDH23 FADD FGF3 GJB2
8 no phenotypic analysis MP:0003012 9.23 FADD FGF3 GJB2 GJB3 GJB6 MYH9

Drugs & Therapeutics for Inner Ear Disease

Drugs for Inner Ear Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
2
Histamine Approved, Investigational Phase 4,Phase 3,Not Applicable 51-45-6, 75614-87-8 774
3
Dimenhydrinate Approved Phase 4,Phase 3 523-87-5 441281
4
Betahistine Approved, Investigational Phase 4,Not Applicable 5638-76-6 2366
5
Caffeine Approved Phase 4 58-08-2 2519
6 Piracetam Approved, Investigational Phase 4 7491-74-9
7
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
10
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
11
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
12
Glycerol Approved, Investigational Phase 4 56-81-5 753
13
Thymol Approved Phase 4 89-83-8 6989
14
Phenol Approved, Experimental Phase 4,Not Applicable 108-95-2 996
15
Ethanol Approved Phase 4 64-17-5 702
16
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
18
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3 302-25-0
19
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3 2921-57-5
20
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
21
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
23
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
26
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
28 Tocotrienol Investigational Phase 4 6829-55-6
29
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3 2920-86-7
30 Anticoagulants Phase 4
31 Hypoglycemic Agents Phase 4
32 Fibrinolytic Agents Phase 4
33 Antimetabolites Phase 4,Phase 3
34 Lipid Regulating Agents Phase 4
35 Glucuronyl glucosamine glycan sulfate Phase 4
36 Hypolipidemic Agents Phase 4
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38
Histamine Phosphate Phase 4,Phase 3,Not Applicable 51-74-1 65513
39 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Histamine Antagonists Phase 4,Phase 3,Not Applicable
42 Histamine H1 Antagonists Phase 4,Phase 3,Not Applicable
43 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Pharmaceutical Solutions Phase 4,Phase 2
46 Vasodilator Agents Phase 4,Phase 1,Not Applicable
47 Sildenafil Citrate Phase 4 171599-83-0
48 Phosphodiesterase Inhibitors Phase 4,Not Applicable
49 Citrate Phase 4
50 Phosphodiesterase 5 Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
2 Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets Completed NCT02718846 Phase 4 Meniace;Isobide
3 Efficacy of Local Overpressure Treatment for Meniere's Disease Completed NCT00831688 Phase 4
4 Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy Completed NCT00160238 Phase 4 Betahistine 24 mg bid (Betaserc)
5 Sildenafil For Meniere's Disease Completed NCT00145483 Phase 4 Sildenafil
6 Effect of Caffeine Intake in Vestibular Function Completed NCT02825199 Phase 4
7 Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo Completed NCT01890538 Phase 4 Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
8 Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo Completed NCT02253524 Phase 4 Dimenhydrinate;Metoclopramide
9 Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV Completed NCT02031692 Phase 4 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
10 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
11 Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Completed NCT00765635 Phase 4 drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
12 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Recruiting NCT02530931 Phase 4 Gadolinium
13 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Recruiting NCT02529475 Phase 4 Gadoteric acid
14 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
15 A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation Withdrawn NCT00474409 Phase 4 Merislon
16 Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin Unknown status NCT02112578 Phase 3 Meclizine;Dimenhydrinate
17 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
18 Conventional Versus Virtual Reality Based Vestibular Rehabilitation Completed NCT01442623 Phase 2, Phase 3
19 Study of Lamotrigine to Treat Ménière's Disease Completed NCT02158585 Phase 3 Lamotrigine;Placebo
20 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Completed NCT02612337 Phase 3 OTO-104;Placebo
21 Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease Completed NCT01454726 Phase 3
22 Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease Completed NCT00802529 Phase 2, Phase 3 Methylprednisolone;Gentamicin
23 The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo Completed NCT02029508 Phase 3
24 Promethazine vs. Lorazepam for Treatment of Vertigo Completed NCT01827293 Phase 3 Promethazine;Lorazepam
25 Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT01366430 Phase 3
26 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT00810641 Phase 3
27 Canalith Repositioning Procedure for BPPV in Primary Care Completed NCT00182273 Phase 3
28 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
29 Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Recruiting NCT03664674 Phase 3 OTO-104;Placebo
30 Rizatriptan for Episodic Dizziness in Vestibular Migraine Recruiting NCT02447991 Phase 2, Phase 3 Rizatriptan;Placebo
31 Caroverin and Inner Ear Diseases Suspended NCT01174979 Phase 3 Caroverin
32 Autoimmunity in Inner Ear Disease Terminated NCT00000361 Phase 3 Corticosteroids;Methotrexate
33 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02768662 Phase 3 OTO-104
34 Study of OTO-104 in Subjects With Unilateral Meniere's Disease Terminated NCT02717442 Phase 3 OTO-104;Placebo
35 A 6-Month Extension Study of OTO-104 in Meniere's Disease Terminated NCT02706730 Phase 3 OTO-104
36 Famvir for Treatment of Hearing in Unilateral Meniere's Disease Terminated NCT01526408 Phase 3 Famciclovir;Placebo
37 Visual Feedback Goggle for Positional Vertigo Treatment Unknown status NCT00729885 Phase 1, Phase 2
38 Latanoprost for the Treatment of Menière's Disease Unknown status NCT01973114 Phase 2 Latanoprost
39 Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy Unknown status NCT02247648 Phase 2 tramadol;Placebo
40 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
41 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
42 Study to Evaluate SPI-1005 in Adults With Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
43 A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom Completed NCT02265393 Phase 2 OTO-104;Placebo
44 OTO-104 for the Treatment of Meniere's Disease Completed NCT01412177 Phase 2 OTO-104;Placebo
45 A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Completed NCT02299804 Phase 2 Levophencynonate Hydrochloric;Placebo
46 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT02046980 Phase 2
47 Effect of V0251 in Acute Vertigo Completed NCT01583738 Phase 2 V0251;placebo
48 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
49 Treatments for Benign Paroxysmal Positional Vertigo (BPPV) Completed NCT00000359 Phase 2
50 A Trial of Booklet Based Self Management of Dizziness Completed NCT00732797 Phase 2

Search NIH Clinical Center for Inner Ear Disease

Cochrane evidence based reviews: labyrinth diseases

Genetic Tests for Inner Ear Disease

Anatomical Context for Inner Ear Disease

MalaCards organs/tissues related to Inner Ear Disease:

41
Brain, Testes, Bone, Lung, Thyroid, Skin, Kidney

Publications for Inner Ear Disease

Articles related to Inner Ear Disease:

(show top 50) (show all 144)
# Title Authors Year
1
Immune-Mediated Inner Ear Disease: Diagnostic and therapeutic approaches. ( 29525415 )
2018
2
Autoimmune Inner Ear Disease: Immune Biomarkers, Audiovestibular Aspects, and Therapeutic Modalities of Cogan's Syndrome. ( 29850616 )
2018
3
Intratympanic gadolinium magnetic resonance imaging supports the role of endolymphatic hydrops in the pathogenesis of immune-mediated inner-ear disease. ( 29888688 )
2018
4
Imaging in autoimmune inner-ear disease and endolymphatic hydrops, bone cement for improving hearing outcomes in stapes surgery, and the reporting of results. External ear canal cholesteatoma: a hypothesis. ( 30019670 )
2018
5
Autoimmune inner ear disease secondary to Hashimoto's thyroiditis: a case report. ( 30181832 )
2018
6
Autoimmune inner ear disease (AIED): A diagnostic challenge. ( 30376736 )
2018
7
Can positron emission tomography support the characterization of immune-mediated inner ear disease? ( 30032987 )
2018
8
The Balance of Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Autoimmune Inner Ear Disease Patients. ( 28696822 )
2017
9
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. ( 26885370 )
2016
10
Anterior Inferior cerebellar artery infarction misdiagnosed as inner ear disease. ( 29553620 )
2016
11
Systematic Review of Treatments for Autoimmune Inner Ear Disease. ( 26485595 )
2015
12
Progression of autoimmune inner ear disease to labyrinthitis ossificans: clinical and radiologic correlation. ( 25738715 )
2015
13
Current understanding of the pathogenesis of autoimmune inner ear disease: a review. ( 25847404 )
2015
14
Paraneoplastic syndrome: a masquerade of autoimmune inner ear disease. ( 25427223 )
2015
15
N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients. ( 26392121 )
2015
16
Diffuse systemic sclerosis presenting as Meniere's disease-like symptoms as part of autoimmune inner ear disease. ( 26040060 )
2015
17
Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. ( 25133431 )
2014
18
The role of intracochlear drug delivery devices in the management of inner ear disease. ( 25347140 )
2014
19
IL-1I^ inhibition in autoimmune inner ear disease: can you hear me now? ( 25133418 )
2014
20
Ocular vestibular evoked myogenic potentials induced by bone-conducted vibration in patients with unilateral inner ear disease. ( 24215219 )
2014
21
Cochlin in autoimmune inner ear disease: Is the search for an inner ear autoantigen over? ( 25199741 )
2014
22
New prospects in the diagnosis and treatment of immune-mediated inner ear disease. ( 25332908 )
2014
23
An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. ( 25203561 )
2014
24
Cogan's syndrome: an autoimmune inner ear disease. ( 22846458 )
2013
25
Review of the biologic agents used for immune-mediated inner ear disease. ( 22770424 )
2013
26
Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease. ( 23912888 )
2013
27
Autoimmune inner ear disease preliminary case report: audiometric findings following steroid treatments. ( 23800807 )
2013
28
Developments in delivery of medications for inner ear disease. ( 23560526 )
2013
29
Infliximab for autoimmune inner ear disease: case report and literature review. ( 24125068 )
2013
30
Autoimmune inner ear disease: a retrospective review of forty-seven patients. ( 23817208 )
2013
31
Spectrum of immune-mediated inner ear disease and cochlear implant results. ( 22991211 )
2012
32
Inner ear disease and benign paroxysmal positional vertigo: a critical review of incidence, clinical characteristics, and management. ( 21837242 )
2011
33
Autoimmune inner ear disease in children. ( 21178803 )
2011
34
A pilot study of rituximab in immune-mediated inner ear disease. ( 20980741 )
2011
35
Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research. ( 21251965 )
2011
36
IL-1I^ is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. ( 21199898 )
2011
37
High dose combination pertussis toxin induces autoimmune inner ear disease in Sprague-Dawley rats. ( 21366505 )
2011
38
Auditory and vestibular hair cell stereocilia: relationship between functionality and inner ear disease. ( 21774850 )
2011
39
Extraintestinal Crohn's disease mimicking autoimmune inner ear disease: a histopathological approach. ( 20523038 )
2011
40
You're the flight surgeon. Labyrinthine dysfunction. ( 21888282 )
2011
41
Guest editorial: drug delivery for treatment of inner ear disease: current state of knowledge. ( 20215911 )
2010
42
Benign paroxysmal positional vertigo secondary to inner ear disease. ( 20723780 )
2010
43
Cochlear implantation outcomes in patients with autoimmune and immune-mediated inner ear disease. ( 20729775 )
2010
44
Drug delivery for treatment of inner ear disease: current state of knowledge. ( 19952751 )
2010
45
Labyrinthitis ossificans secondary to autoimmune inner ear disease: a previously unreported condition. ( 20416474 )
2010
46
Dr. Takeda's research on MAcniA"re disease and inner ear disease. Preface. ( 20185942 )
2010
47
Cochlear implantation in patients with autoimmune inner ear disease including cogan syndrome: a comparison with age- and sex-matched controls. ( 21082747 )
2010
48
Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. ( 19395984 )
2009
49
Immunosuppressive therapy for autoimmune inner ear disease. ( 19885385 )
2009
50
Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease. ( 19365153 )
2009

Variations for Inner Ear Disease

Expression for Inner Ear Disease

Search GEO for disease gene expression data for Inner Ear Disease.

Pathways for Inner Ear Disease

GO Terms for Inner Ear Disease

Cellular components related to Inner Ear Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.55 ATP6V0A4 ATP6V1B1 GJB6 MYO7A SLC26A4
2 vacuolar proton-transporting V-type ATPase complex GO:0016471 9.26 ATP6V0A4 ATP6V1B1
3 gap junction GO:0005921 9.13 GJB2 GJB3 GJB6
4 connexin complex GO:0005922 8.8 GJB2 GJB3 GJB6

Biological processes related to Inner Ear Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 inner ear morphogenesis GO:0042472 9.61 ATP6V1B1 KCNQ4 MYO7A
2 aging GO:0007568 9.56 GJB2 GJB6 MPO TIMP1
3 inner ear development GO:0048839 9.5 GJB2 GJB6 MYO7A
4 negative regulation of growth of symbiont in host GO:0044130 9.49 MPO TNF
5 sensory perception of light stimulus GO:0050953 9.48 CDH23 MYO7A
6 death-inducing signaling complex assembly GO:0071550 9.46 FADD TNF
7 equilibrioception GO:0050957 9.4 CDH23 MYO7A
8 necroptotic signaling pathway GO:0097527 9.37 FADD TNF
9 cell communication GO:0007154 9.33 GJB2 GJB3 GJB6
10 sensory perception of sound GO:0007605 9.28 ATP6V0A4 ATP6V1B1 CDH23 COCH GJB2 GJB6
11 regulation of pH GO:0006885 9.13 ATP6V0A4 ATP6V1B1 SLC26A4

Molecular functions related to Inner Ear Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 FADD TIMP1 TNF
2 microfilament motor activity GO:0000146 9.26 MYH9 MYO7A
3 gap junction channel activity GO:0005243 8.96 GJB2 GJB3
4 actin-dependent ATPase activity GO:0030898 8.62 MYH9 MYO7A

Sources for Inner Ear Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....